Jeffrey S. Hatfield Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for Jeffrey S. Hatfield.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of Jeffrey S. Hatfield. Jeffrey S. Hatfield is a Director in AMBIT BIOSCIENCES CORP ($AMBI) and an Chief Executive Officer in Vitae Pharmaceuticals, Inc ($VTAE) and a Director in INVIVO THERAPEUTICS HOLDINGS CORP. ($NVIV) and a Director in aTYR PHARMA INC ($LIFE) and an Chief Executive Officer in ZAFGEN, INC. ($ZFGN) and a Director in MIRAGEN THERAPEUTICS, INC. ($MGEN) and a Director in Vir Biotechnology, Inc. ($VIR).
Address: C/O AMBIT BIOSCIENCES CORPORATION 11080 ROSELLE STREET SAN DIEGO 92121 CA
Companies in which Jeffrey S. Hatfield is an Insider
AMBIT BIOSCIENCES CORP
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Jeffrey S. Hatfield: Director
Holdings: 0 shares
Latest Transaction: Nov 12 2014
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
aTYR PHARMA INC
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Jeffrey S. Hatfield: Director
Holdings: 0 shares
Current Value: $0
Latest Transaction: May 08 2020
$LIFE Market Capitalization: $78.27M
$LIFE Previous Close: $3.40
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
INVIVO THERAPEUTICS HOLDINGS CORP.
Industry: SURGICAL & MEDICAL INSTRUMENTS & APPARATUS [3841]
Position of Jeffrey S. Hatfield: Director
Holdings: 0 shares
Current Value: $0
Latest Transaction: Jan 23 2018
$NVIV Market Capitalization: $139.34M
$NVIV Previous Close: $4.45
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Larimar Therapeutics, Inc.
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Jeffrey S. Hatfield: Chief Executive Officer
Holdings: 0 shares
Current Value: $0
Latest Transaction: Jan 24 2019
$LRMR Market Capitalization: $109.05M
$LRMR Previous Close: $4.10
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Vir Biotechnology, Inc.
Industry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of Jeffrey S. Hatfield: Director
Holdings: 0 shares
Latest Transaction: Dec 11 2020
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Viridian Therapeutics, Inc.\DE
Industry: SERVICES-MEDICAL LABORATORIES [8071]
Position of Jeffrey S. Hatfield: Director
Holdings: 0 shares
Current Value: $0
Latest Transaction: Feb 08 2021
$MGEN Market Capitalization: $9.56M
$MGEN Previous Close: $10.55
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Vitae Pharmaceuticals, Inc
Industry: PHARMACEUTICAL PREPARATIONS [2834]
Position of Jeffrey S. Hatfield: Chief Executive Officer
Holdings: 244,996 shares
Latest Transaction: Oct 25 2016
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD View transactions
Latest Insider Trading Transactions of Jeffrey S. Hatfield
Sentiment: All, AMBI, LIFE, NVIV, LRMR, VIR, MGEN, VTAE
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Feb 08 2021 | MGEN | Viridian Therapeut ... | Hatfield Jeffrey S. | Director | Option Exercise | A | 20.50 | 25,000 | 512,500 | 25,000 | |
| Dec 11 2020 | VIR | Vir Biotechnology, ... | Hatfield Jeffrey S. | Director | Option Exercise | A | 29.43 | 46,500 | 1,368,495 | 46,500 | |
| May 22 2020 | MGEN | MIRAGEN THERAPEUTI ... | Hatfield Jeffrey S. | Director | Option Exercise | A | 0.63 | 24,000 | 15,026 | 24,000 | |
| May 08 2020 | LIFE | aTYR PHARMA INC | Hatfield Jeffrey S. | Director | Option Exercise | A | 3.65 | 1,428 | 5,212 | 1,428 | |
| Jun 21 2019 | MGEN | MIRAGEN THERAPEUTI ... | Hatfield Jeffrey S. | Director | Option Exercise | A | 2.36 | 12,000 | 28,320 | 12,000 | |
| May 10 2019 | LIFE | aTYR PHARMA INC | Hatfield Jeffrey S. | Director | Option Exercise | A | 0.58 | 20,000 | 11,668 | 20,000 | |
| Jan 24 2019 | ZFGN | ZAFGEN, INC. | Hatfield Jeffrey S. | Chief Executive Off ... | Option Exercise | A | 4.63 | 525,000 | 2,430,750 | 525,000 |